FOLH1 and posterior cortical atrophy: PSMA has been validated as a diagnostic and therapeutic target in prostate cancer (PCa), and radionuclide probes-targeted PSMA like 18F-PSMA, 68Ga-PSMA and 177Lu-PSMA was used in diagnosis and treatment of PCa (2).